Your symptoms help decide which back care fits

Movement and medicine can help common back soreness

Most care starts with activity you can tolerate. Short walks and steady exercise can reduce stiffness. You don't need hard exercise during a strong flare.

Physical therapy gives you guided movement for daily tasks. Tell the therapist if an exercise causes strong or lasting soreness. The exercise can change without stopping all activity.

Medicine may ease symptoms, but it won't fix every cause. Safe choices depend on your heart, stomach, kidneys, and other pills. Ask your doctor what each medicine is meant to do.

PRP for back pain needs a clear reason

Biologic therapies are treatments made from part of your own body. PRP (platelet-rich plasma) comes from your blood after a machine spins the sample. This raises the share of platelets, small blood parts that help begin healing.

The provider places the concentrated PRP into the back area chosen after your exam. Studies of PRP in different back areas are small and mixed. It can't promise to rebuild a worn disc or end soreness.

Orthobiologics is a medical name for these blood-based or marrow-based treatments. Regenerative treatments means care intended to support normal repair in the chosen area. Neither term tells you whether the treatment fits your back.

The exam should connect each treatment to your symptoms

A provider will ask when the ache began and which area hurts. The exam checks movement, feeling, and strength in your legs. Your health and medicines also affect the choice.

A QC Kinetix consultation can cover regenerative treatment options after a health review. Medical providers are the people who examine you and oversee your care. Ask which back area the treatment would reach.

Also ask about cost, limits, and follow-up care. Bring old scans if you already have them. Don't order a new scan just for this visit.

Growing weakness or damaged back bones may need surgery

A surgeon's review can matter when leg weakness grows. It can also matter after a major fall damages back bones. You can't tell at home whether damaged bones can safely support you.

Ask which symptom an operation is likely to change. Then ask which soreness may remain afterward. Recovery time and your other health problems matter too.

Care without surgery may fit when no urgent sign exists. That can include exercise, medicine, or a blood-based option. Be wary if anyone promises to rebuild a disc or end soreness for good.

Sources

1. The 2017 American College of Physicians guideline makes a STRONG recommendation that acute and subacute low back pain be treated first with non-drug care - superficial heat, massage, acupuncture or spinal manipulation - because most patients improve over time regardless of treatment, and a STRONG recommendation that chronic low back pain be treated first with exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, motor control exercise, progressive relaxation, EMG biofeedback, low-level laser therapy, operant therapy, cognitive behavioural therapy or spinal manipulation. Drugs are second, and opioids are a weak recommendation of last resort.

   Qaseem A, Wilt TJ, McLean RM, et al. — Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.. Annals of Internal Medicine, 2017. DOI: 10.7326/M16-2367.

2. A 2025 Cochrane overview of 31 Cochrane reviews covering 644 trials and 97,183 adults found that exercise therapies probably reduce chronic low back pain by 15.2 points on a 0-100 scale versus no treatment or usual care and improve function by 6.8 points, that multidisciplinary therapies probably produce a medium pain reduction, that acupuncture probably improves function only slightly versus sham, that traction is probably no different from sham traction, and that spinal manipulation probably makes no difference to function versus placebo in acute low back pain.

   Rizzo RR, Cashin AG, Wand BM, et al. — Non-pharmacological and non-surgical treatments for low back pain in adults: an overview of Cochrane reviews.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD014691.pub2.

3. A meta-analysis of 35 placebo-controlled randomised trials found NSAIDs reduce spinal pain and disability, but by an amount below the threshold for clinical importance: six people must be treated with an NSAID rather than placebo for one additional person to achieve clinically important pain reduction, and NSAIDs raised the risk of gastrointestinal reactions 2.5-fold. The authors conclude that no simple analgesic provides clinically important effects for spinal pain over placebo.

   Machado GC, Maher CG, Ferreira PH, et al. — Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis.. Annals of the Rheumatic Diseases, 2017. DOI: 10.1136/annrheumdis-2016-210597.

4. The OPAL trial randomised 347 people presenting with acute low back or neck pain to guideline care plus a short course of oxycodone-naloxone or guideline care plus an identical placebo. Mean pain at six weeks was 2.78 in the opioid group versus 2.25 in the placebo group - the opioid group did slightly WORSE, and the difference was not statistically significant. The authors call for a change in the frequent use of opioids for these conditions.

   Jones CMP, Day RO, Koes BW, et al. — Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial.. The Lancet, 2023. DOI: 10.1016/S0140-6736(23)00404-X.

5. The only double-blind randomised trial of intradiscal PRP for discogenic low back pain enrolled 47 participants (29 PRP, 18 control) and reported statistically significant improvements in pain, function and satisfaction over EIGHT WEEKS compared with a contrast-agent control. It is a small, single-centre trial, the control group was offered crossover to PRP at 8 weeks, and no disc infection, neurological injury or progressive herniation was reported. The authors themselves call the results promising and say further studies are needed to define who responds.

   Tuakli-Wosornu YA, Terry A, Boachie-Adjei K, et al. — Lumbar Intradiskal Platelet-Rich Plasma (PRP) Injections: A Prospective, Double-Blind, Randomized Controlled Study.. PM&R, 2016. DOI: 10.1016/j.pmrj.2015.08.010.

6. The 2025 ASIPP regenerative-therapy guideline for chronic low back pain - written by the specialty society that performs these procedures - grades the evidence as Level III (fair) for intradiscal PRP, Level III (fair) for intradiscal bone marrow concentrate, Level III (fair) for epidural PRP, Level IV (limited) for facet joint PRP and MSC injections, Level IV (limited) for sacroiliac joint PRP, and very low for functional-spine-unit injections. All 19 recommendations are consensus-based rather than evidence-driven, the panel names the scarcity of high-quality studies as the primary limitation, and it states that most of these therapies are not covered by commercial insurance.

   Manchikanti L, Navani R, Navani A, et al. — Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP).. Pain Physician, 2025.

7. The FDA states verbatim that stem cell products, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products have NOT been 'approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' No stem cell product is approved in the United States for any orthopedic use: the only ones with FDA approval at all are blood-forming cells derived from umbilical cord blood, approved solely for disorders of blood production, and there are currently no FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA.gov, 2025.